The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
0905009 Informal Interpretation
Fair Credit Reporting Affiliate Marketing Regulations; Identity Theft Red Flags and Address Discrepancies Under the Fair and accurate Credit Transactions Act of 2003 - 16 CFR Parts 641, 681, and 698
The Fair Credit Reporting Act: Address Discrepancy Rule
0905006 Informal Interpretation
0905001 Informal Interpretation
0904011 Informal Interpretation
0904010 Informal Interpretation
0904007 Informal Interpretation
0904006 Informal Interpretation
0904003 Informal Interpretation
0904002 Informal Interpretation
Bristol-Myers Squibb Company
Drug maker Bristol-Myers Squibb Company (BMS) agreed to pay $2.1 million – the largest fine allowed by law – for failing to inform the FTC of agreements reached with Apotex, Inc., regarding potential generic competition to its blockbuster drug Plavix. BMS’s conduct violated a 2003 FTC Order and the Medicare Modernization Act, which requires that certain drug company agreements be accurately reported to both the Commission and the U.S. Department of Justice. The complaint alleges that BMS failed to disclose that, as part of a patent settlement in which Apotex agreed not to launch its generic version of Plavix for several years, BMS also orally stated, among other things, that it would not compete with Apotex during the first 180 days after Apotex did market its new generic drug.